CYTOTOXIC AND GENOTOXIC EFFECTS OF NICKEL OXIDE NANOPARTICLES ON HeLa CELLS
Objective: Nickel oxide nanoparticles (NiO-NPs) are used invarious applications, and their increasing use has stimulated extensive studies both in vivo and in vitro. Nevertheless, their activity in cancer cells and thus the possibility of developing new anticancer drugs still remain controversial. T...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Istanbul University Press
2024-10-01
|
| Series: | Sabiad |
| Subjects: | |
| Online Access: | https://cdn.istanbul.edu.tr/file/JTA6CLJ8T5/A87079BAEDCD4D42A051BEF8FD59A635 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Objective: Nickel oxide nanoparticles (NiO-NPs) are used invarious applications, and their increasing use has stimulated extensive studies both in vivo and in vitro. Nevertheless, their activity in cancer cells and thus the possibility of developing new anticancer drugs still remain controversial. Therefore, this study was conducted to specifically investigate the cytotoxicity and genotoxicity of NiO-NPs in human cervical carcinoma (HeLa) cells. Material and Methods: The cytotoxicity of NiO-NPs was evaluated using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), lactate dehydrogenase (LDH), and neutral red uptake (NRU) cytotoxicity assays. A comet assay was performed to determine the genotoxicity of NiO-NPs. Results: The half maximal inhibitory concentration (IC50) values were 419.6, 316.4, and 119.3 µg/mL in the MTT, NRU, and LDH assays, respectively. The comet assay revealed that NiO-NPs caused significant induction of DNA damage in the exposed HeLa cells. The tail intensity was 18.20% at 120 μg/mL. Conclusion: NiO-NPs were cytotoxic and genotoxic to HeLa cells. Although NiO-NPs may be hazardous for a normal cell line, the effects observed on HeLa cells indicate that NiO-NPs can be proposed as a novel anticancer agent. However, the potential for NiO-NPs in cancer treatment will require additional and comprehensive studies on other cancer cell lines. |
|---|---|
| ISSN: | 2651-4060 |